Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep - morecoffee's post about HDAC lead me to your same google search of Celgene+Kevetrin, which lead to the search result about Celgene lists Kevetrin in patent, which sparked my memory about the list that The Progressive clued us in to a while ago, which Whoops has just re-posted. It's great knowing the 'scientists' are aware and have been for some time, hopefully enough of some time such that an announcement is "just around the corner", to use the parlance of our time
It's been answered: with Celgene mentioning Kevetrin in a patent app - the answer is yes, they wish to study a drug like Kevetrin. Not sure if this gives any validity to the Celgene rumors, but shoot man - somethings got to happen soon, doesn't it??? I've waited years, what's another weekend, or two, or eight. It's actually been a blessing perhaps - all this dreadful delay has given me enough time to acquire into figure six.
United States Patent Application 20140046057
Kind Code A1
Cohen; Benjamin M. ; et al. February 13, 2014
Assignee: Celgene Corporation
Summit
NJ
[0565] In one embodiment, the second active agent is HDAC inhibitor. In one embodiment, the HDAC inhibitor is vorinostat, romidepsin, panobinostat, valproic acid, belinostat, mocetinostat, abexinostat, entinostat, SB939, resminostat, givinostat, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, sulforaphane, kevetrin, or trichostatin A.
"We believe we have identified the Mechanism of Action of Kevetrin which explains why Kevetrinâ„¢ is so effective in a broad spectrum of cancers," says Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. "Downregulation of HDAC2 also explains why Kevetrinâ„¢ is so effective in drug resistant tumors. Furthermore, since Kevetrinâ„¢ acts in a non-genotoxic manner and induces potent antitumor activity, we feel that Kevetrinâ„¢ is a clear standout from all other anticancer drugs. In all my years as a cancer researcher, I haven't seen a drug act like Kevetrinâ„¢ which is targeting and reacting with virtually every type of cancer."
[BEVERLY, MA--(Marketwire - Jan 17, 2012) - Cellceutix Corporation (OTCBB: CTIX)]
hmm... Is Celgene presenting at ASCO anything that lists wishes to study with HDAC2 inhibitors?
It's a difference in applied value, CTSO is looking for growth in sales and turning their books positive several quarters down the road which should lead to a fairly regular increase in capitalization as they achieve. CTIX has it's value applied based on trial results to determine how many of their three active trial blockbusters may be acquired or partnered for instantaneous multiplication of their capitalization. CTSO - slow and steady to a 4X multiple in a couple years, CTIX - stairstep and irratic to a 100X multiple in a couple years.
I like CTSO's chance of doubling in 6 months and have bought accordingly. I like CTIX's chance of going up 10 fold in 6 months (results of all three trials might be in by then and all are progressing quite excellently).
CTSO is quite high on my list. It is well below CTIX however...
Did you see this on level2? I know that my buy this morning posted as a sell on the trades list because it filled at the bid price for that time discretization. Games do get played to get nice buys through.
Really? You reversed my point about decreasing share supply so that you could be pompous again.
I agree, sure - to a point. In control of all the day's selling? I question the pompousness of it all.
Are you stating that over 60% of today's volume was you alone selling? You starting to worry that you are making a mistake yet? Seems there is no shortage of demand on this green close day. Makes no sense why you wouldn't curtail the supply and ask a higher price when you could obviously get one. You're either not an economist or you're full of it or both.
SAN DIEGO, CA, May 15, 2014 (Marketwired via COMTEX) -- Overland Storage OVRL +3.10% , a trusted global provider of unified data management and data protection solutions across the data lifecycle, today reported financial results for its fiscal 2014 third quarter ended March 31, 2014.
Eric Kelly, President and CEO of Overland Storage, said, "During the quarter, we completed the first phase of our continuing integration of Tandberg Data ahead of plan, and we continue to make good progress with our integration activities which are projected to be complete by the end of the calendar year. Through this process, we remain focused on leveraging the increased scale and resources of the combined company to maximize the growth opportunities we see with our expanded product and service portfolio, as well as the launch of our integrated virtualization and storage solutions, which we expect to occur in the next few months. We are seeing very positive customer responses to the combination of Overland and Tandberg, and believe that once fully integrated, we will achieve the operational efficiencies to enable us to become a profitable and growing company."
Recent Highlights:
-- Completed acquisition of Tandberg Data Holdings S.a r.l., a privately held global leader of data storage and data protection solutions on January 21, 2014.
-- Executing on strategic relationship with Sphere 3D to deliver a new purpose built virtual desktop infrastructure (VDI) appliance and software defined storage solution, which will include Overland's NAS platform and be delivered through Overland's channel partners.
http://www.marketwatch.com/story/overland-storage-reports-third-quarter-fiscal-2014-results-2014-05-15
Ha, that's what makes it so obvious - still negative shares, still trying to cover. The argument a while ago was that CTSO would probably not be able to maintain 50% sales increases, but they demolished that target. Now the fear mongering is about compairing same quarter to same quarter, trying to act as if that is not how it is always done. Perhaps the poster has a misunderstanding on fiscal cycles, especially when hospitals make product orders, or whatever. The despiration from this board's local contrarian is quite interesting.
Over 6.7 million shares is claimed, yet still trying to cover - must have screwed up bigtime!
Wanted 50% Q-over-Q, got 81% Way to go CTSO!!!
It will happen - if I learned something over the nearly three years I have been invested here: good news is on the way, but just don't plan on seeing it coming. We will wake up one day to something that directly causes a move (data release, some pharma deal, ...) or something that indirectly causes a move (institutional buying, a data leak, ...), and I'm here for it and I think it has all the potential to be quite sudden indeed.
One can make the assumption that the 'big boys' are not interested because we have heard nothing and the share price has not increased.
I think another possibility is that part of Leo's job is to decline the interest. Because, what 'big boy' won't begin with a low-ball test? And I cannot see the professionalism in making the initial interest known to the public, beyond the fact that non-disclosure agreements were signed well in advance of any communication regarding details. Leo also is fully aware of what value Cellceutix holds. So perhaps, while discussion are ongoing, Leo keeps it close to the vest and the bigboys with the interest don't want to drive up the stock price and give Leo all the leverage and aspiration to go shopping for better offers. Seems reasonable to me, but let me know what I have wrong.
All the strategy in this type of deal making is something I know nothing about, but I sure bet Leo knows something about it!
I like that thought - perhaps Leo is waiting for 'all' of the cohort 7 information before he generates the PR. An 'all' that happens to include p21 assays and all of the cancer growth characterizations - might be wishful thinking, but I like the thought!
When your patience wears thin then attack the company. When attacks against the company don't get any traction then go after management and their family members. I am so glad I will never meet these type of posters in actual life.
You're not doing yourself any favors by assuming you know how the founding of an unrelated corporation took place. If this unrelated corporate founding is your primary reason for unloading your CTIX shares prior to CTIX launching multiple human trials of potentially quite significant pharmaceutical values, well... you have no one to blame but yourself. Fear not, your financial well-being is not doomed - you can buy shares tomorrow and start feeling good about your portfolio along with everyone else on this board.
Fathers who are proud of their sons, sons that are proud of their fathers, father-son ventures that arise from such - these things do exist, they're not just fairytales, but don't feel bad about it, don't take it out on the father-son teams that give it a go.
I'm hoping it happens when Q1 data is realeased in the next week or two showing greater than 50% increase in sales quarter over quarter.
Nice development - glad I stayed the course. Has anyone been around SBFM long enough to have an idea of where this tops out tomorrow?
That is after the first and second forward split
"Facts are lazy and facts are late": by the time CTIX's clinical trial result facts about efficacy are released, it will be too late for those that waited - leaving them "Crosseyed and Painless".
Haha yep - math is powerful, logical, and does not yield to subjective critique or conjecture. And the math says buy CTIX and hold most of it for a couple years. Of course some subjective critique may be needed to get some starting assumptions: go to Pharmacyclics' website, check out their R&D section and their pipeline, go to Cellceutix's website, check out their pipeline section, compare. Then do math: at $150 pcyc had a cap of 11.25B, if we give equal valuation and assume today's OS numbers for simplicity, ctix will be at $107 eventually. I would argue CTIX's pipeline has advantages regarding both strength and breadth across different pharmaceutical catagories, so even as share numbers may change with respect to Aspire,total OS, etc., $107 is potentially a conservative value. Of course trial results will be the determining factor.
Totally. y=m*x+b, for about 30 months starting in late 2011 pharmacyclics m =~ $5/month. With CTIX's results timing stackup and the pipeline robustness with multiple blockbuster potentials, perhaps we can beat PCYC's slope? Could we climb from $2 to $150 in less than 30 months? I can't wait for our value escalation to begin...
I think it is well within the realm of possibility. Regardless of what either you think or I think, the recent 10K now being fact along with the knowledge that many Q4'13 sales had to be pushed onto Q1'14 books due to freight logistics, the upcoming 10Q is likely to show additional progress leading to the conclusion that emotion-free mathematically-corroborated logic suggests that one go long and stay long. In my opinion that is - haha!
You may be correct - here, let's do the actual math: we'll start with a unity value for last year's sales at "1.0" to make it easy for you. Add 50% Q1 to 1.5, add 50% Q2 to 2.25, add 50% Q3 to 3.375, and add 50% one more time for Q4 to 5.0625. Yep, 50% quarter over quarter is only a 406.25% gain, not 422% - my bad! Haha
Once again we are agreeing that the analysts' projections for $1.00 could be spot on.
Interesting, at CTSO's current rate of growth at over 400% they will be at that value by year end. Turns out the analysts who put a target at $1.00 could be spot on. Hell, we might even end up doing better than that!
Very nice - I thought this progress was likely to drive upward revisions on price targets. Great to see, thanks!
Perhaps all those that trade based on what CTSO is are done and those that invest based on what CTSO will be can take over. With the year over year, quarter over quarter, record breaking sales advancements, investing based on what CTSO will be makes all the sense in the world.
422% increase in sales? Enormous! If you didn't see this coming you were blind, hints dropped in PRs, another hint that many of q4 sales had to be left off and will add to q1 2014 - this will keep getting better. I appreciate all the idiotic sellers, I was happy to be a buyer today. Finished off my cash pool at .21 :) Looking forward to tomorrow...
Exactly.
How long do you want to be sick? Oh, not long? Take Brilacidin.
How long do you want to suffer psoriasis? Oh, never again? Take Prurisol.
How long do you want to fear your cancer? Oh, no longer? Take Kevetrin.
How long do you want to work for the man? Oh, not much longer? Invest in Cellceutix with pride!
Not only the insurance companies, the patients will pick Brilacidin. You have a couple choices: take Dapto and deal with the pain and discomfort of your sever infection for the next week that Dapto requires, OR take Brila for a day. Umm... Gimmie Brila!
Wow, first time you've given credit when credit is due - thank you!
(Edit: ha, i assumed you replied to my most recent post, figures it was something way postdated.)
I would assume that the original purchase was made under the assumption that the .3125 warrants will be worth something, meaning they assume their .25 purchase will be worth more than .3125 in the future. Buy some at .25, keep until they're worth significantly more than .3125, exercise your warrants, win once then win again bigtime. Anything else seems convoluted and not necessary, but then I've never had to argue anything to a firm's investment board so I may be off base.
Was the PR 2 weeks ago about Prurisol IND submitted and trial beginning in 30 days (sans additional FDA request) not sufficient Ovi? I agree with you - those that backed off because 'nothing will happen here for months' are likely to be disappointed.
I think the upcoming 10K should please. We got a hint in the recent PR: "CytoSorbents expects to report 2013 revenues of approximately $2.4 million, including international CytoSorb® sales in the range of $840,000 - 870,000 in its first full year of commercialization." That is almost double of 2012, which was quadruple of 2011 - increasing revenue year over year with an expanding sales force and user base to go along with overall product advancements. I think this has no where to go but up.
Well said. The future is brighter here than perhaps all of my other investments combined! The 2012 ride from 0.50 to 2.00 will be put to shame.